Cardinal Health (CAH) Earnings: FY Adjusted EPS Projected at High End of $7.75-$7.90 Range

Cardinal Health on Smartkarma

Analysts on Smartkarma are bullish on Cardinal Health, Inc., with Value Investors Club highlighting the strong performance under CEO Jason Hollar. The company has shown double-digit EPS growth, engaged in share repurchases, and set ambitious three-year growth targets. Despite challenges such as generic price fluctuations, Cardinal Health is strategically transitioning to higher-margin services for enhanced growth and profitability.

Additionally, Baptista Research echoes a positive sentiment, emphasizing Cardinal Health‘s strong financial and operational results in the first quarter of fiscal year 2025. The company’s Pharmaceutical and Specialty Solutions segment drove significant growth, with CEO Jason Hollar’s effective management leading to a 16% growth in segment profit. Demand across various pharmaceutical categories, especially specialty and consumer health, has played a crucial role in Cardinal Health‘s recent success.

A look at Cardinal Health Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Cardinal Health, Inc. provides a wide range of products and services to healthcare providers and manufacturers, including pharmaceutical distribution, healthcare product manufacturing, and consulting services. With a strong focus on resilience and growth, as indicated by its high scores in these areas, Cardinal Health seems well-positioned for long-term success in the healthcare industry. Its solid momentum score also suggests positive market sentiment and potential for continued performance. While the company lacks a high value score, its emphasis on dividends and growth bode well for investors seeking stable returns and opportunities for expansion.

Overall, Cardinal Health‘s strategic focus on resilience, growth, and momentum reflects a positive long-term outlook for the company. By leveraging its expertise in pharmaceutical distribution and healthcare products, Cardinal Health is poised to capitalize on industry trends and emerging opportunities. With a solid foundation in place, including a strong dividend score, Cardinal Health appears to be a strong contender in the healthcare sector with potential for sustained growth and value creation.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma